Takeda』s TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to

OSAKA, Japan & CAMBRIDGE, Mass. — (BUSINESS WIRE) — Takeda (TSE:4502/NYSE:TAK) today announced that the Phase 3 SHP643-301 study (NCT04070326) evaluating the safety profile and pharmac…